A Study to Evaluate INCA033989 Administered in Participants With Myeloproliferative Neoplasms
Status:
Recruiting
Trial end date:
2028-10-29
Target enrollment:
Participant gender:
Summary
This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity
(DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion
(RDE) of INCA033989 administered in participants with myeloproliferative neoplasms.